US FDA's Regulatory Pipeline Includes DTC, Inspection Requirement Updates
Executive Summary
Additionally, potential regulation to require clinical study sponsors to promptly report suspected data falsification seems to have found new life after being listed as inactive in July update of the Unified Agenda.
You may also be interested in...
Biologics Exclusivity: Key Questions Unlikely To Have Clear Answers From US FDA
FDA’s embrace of biosimilars as part of the drug pricing response means a flurry of guidances coming soon. But don’t expect much clarity on key issues for innovators, like the boundaries of 12-year exclusivity and whether it will apply to NDA products that transition to BLAs, says a former CDER attorney.
Biologics Exclusivity: Key Questions Unlikely To Have Clear Answers From US FDA
FDA’s embrace of biosimilars as part of the drug pricing response means a flurry of guidances coming soon. But don’t expect much clarity on key issues for innovators, like the boundaries of 12-year exclusivity and whether it will apply to NDA products that transition to BLAs, says a former CDER attorney.
Generic Labeling Rule Dies In Latest Reg Agenda, But Electronic Labeling Is Reborn
US FDA also indicated plans to update definition of biologic product and propose a one-page Patient Medication Information in the latest Unified Agenda.